David N. Gordon's most recent trade in Aclaris Therapeutics Inc was a trade of 2,631 Common Stock done at an average price of $17.0 . Disclosure was reported to the exchange on July 13, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.98 per share. | 13 Jul 2021 | 2,631 | 147,447 (0%) | 0% | 17.0 | 44,675 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 6,000 | 6,000 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2021 | 6,000 | 150,078 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 87,500 | 0 | - | - | Restricted Stock Units | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Jun 2021 | 87,500 | 195,992 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 21.50 per share. | 01 Jun 2021 | 31,114 | 150,878 (0%) | 0% | 21.5 | 668,808 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.71 per share. | 01 Jun 2021 | 9,115 | 186,877 (0%) | 0% | 22.7 | 207,024 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 01 Jun 2021 | 6,800 | 144,078 (0%) | 0% | 22.3 | 151,401 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 23.57 per share. | 01 Jun 2021 | 4,885 | 181,992 (0%) | 0% | 23.6 | 115,142 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 99,500 | 99,500 | - | - | Employee Stock Option (Right to Buy) | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2021 | 28,400 | 28,400 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 20,600 | 41,200 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 20,600 | 108,135 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 8,297 | 110,772 (0%) | 0% | - | Common Stock | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 8,297 | 24,892 | - | - | Restricted stock units | |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 24.06 per share. | 01 Mar 2021 | 5,660 | 102,475 (0%) | 0% | 24.1 | 136,180 | Common Stock |
| Aclaris Therapeutics Inc | David N. Gordon | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 23.25 per share. | 01 Mar 2021 | 2,280 | 108,492 (0%) | 0% | 23.3 | 53,010 | Common Stock |